Affiliation:
1. Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD.
Abstract
Caffeine is commonly prescribed in the NICU to treat apnea of prematurity. This review is an update based on current knowledge of the mechanisms of action, pharmacologic properties, clinical effects, and safety of caffeine in the neonatal population. Recent studies of caffeine in the neonatal population confirm its efficacy in treating apnea-related symptoms and reveal additional significant benefits with minimal short-term, and no long-term, adverse effects.
Publisher
American Academy of Pediatrics (AAP)
Subject
Pediatrics, Perinatology and Child Health
Reference55 articles.
1. Caffeine impact on neonatal morbidities;Aranda;J Matern Fetal Neonatal Med,2010
2. Pharmacologic Reviews: Clinical pharmacology of caffeine in the newborn;Natarajan;Neoreviews,2007
3. Trends in caffeine use and association between clinical outcomes and timing of therapy in VLBW infants;Dobson;J Pediatr
4. Treatment of apnea of prematurity;Bhatt-Mehta;Paediatr Drugs,2003
5. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use;Fredholm;Pharmacol Rev,1999
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献